LUPRON DEPOT-PED 45 MG FOR 6-MONTH ADMINISTRATION1
LUPRON DEPOT-PED is indicated for the treatment of pediatric patients with Central Precocious Puberty (CPP).
In the clinical study for LUPRON DEPOT-PED 45 mg for 6-month administration, the most common (≥4%) adverse reactions were:
Please see additional Important Safety Information below.
Please see full Prescribing Information.
Reference: 1. LUPRON DEPOT-PED [package insert]. North Chicago, IL: AbbVie Inc.
US-LUPR-230014
You are leaving this website. Links to all outside websites are provided as a convenience to our visitors and do not imply an endorsement or recommendation by AbbVie. AbbVie accepts no responsibility or liability for the content or services of other websites.